Part 1: Why test?
Prof Cora Sternberg, scientific co-chair of the 2013 European Cancer Conference, discusses the results of a study that found the prostate-specific antigen test to be harmful.
Prof Boniol, Research Director at the International Prevention Research Institute (iPRI) and Professor at the Strathclyde Institute for Global Public Health at iPRI, Lyon, France, told the congress that the total harm men experience in terms of impotence and incontinence, and the side-effects from prostate cancer treatments, severely affects their quality of life, and should further discourage the use of PSA testing for prostate cancer screening.
Part 1: Why test?
Part 2: How to get biopsies for testing?
Part 3: Managing testing efficiencies – How to optimise next generation sequencing and HRR testing
First real-world study of penile cancer in Bolivia reveals high HPV-related rates and advanced disease
Mobile prostate cancer screening clinic can help address barriers to serving high-risk communities
Gaza's cancer patients: Navigating the dual struggle of illness and war
Cancer in emergencies: What can we do better to protect the most vulnerable?
Tele-mentoring: Impact of project ECHO
Powering equity in cancer care through digital health